title: Should sponsors and DSMBs share interim results across trials?
authors.forename: Seema K
authors.initials: SK
authors.lastname: Shah
authors.forename: Liza
authors.initials: L
authors.lastname: Dawson
authors.forename: Dennis O
authors.initials: DO
authors.lastname: Dixon
authors.forename: Reidar K
authors.initials: RK
authors.lastname: Lie
mesh_terms: D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000627:therapeutic use; D026661:Clinical Trials Data Monitoring Committees / Q000941:ethics*; D002986:Clinical Trials as Topic / Q000941:ethics* / Q000379:methods*; D003219:Confidentiality / Q000941:ethics*; D005260:Female; D015658:HIV Infections / Q000188:drug therapy / Q000517:prevention & control* / Q000635:transmission; D006801:Humans; D007231:Infant, Newborn; D018445:Infectious Disease Transmission, Vertical / Q000517:prevention & control*; D007373:Interinstitutional Relations; D019829:Nevirapine / Q000008:administration & dosage / Q000627:therapeutic use; D011247:Pregnancy; D015215:Zidovudine / Q000008:administration & dosage / Q000627:therapeutic use
chemical_list: D019380:Anti-HIV Agents; D015215:Zidovudine; D019829:Nevirapine